Neuroblastoma (NB) is the most common extracranial tumor in children and accounts for around 15% of all pediatric oncology deaths. The treatment of NB includes surgery, chemotherapy, and radiotherapy. Unfortunately, most children with NB present with advanced disease, and more than 60% of patients with high-risk features will have a poor prognosis despite intensive therapy. Agonists of the nuclear receptor peroxisome proliferator-activated receptor \( \gamma \) (PPAR\( \gamma \)) have been shown to have pleiotropic effects, including antineoplastic effects. The studies that addressed the role and the possible mechanism(s) of action of PPAR\( \gamma \) in NB cells are reviewed.

Copyright © 2008 Alessandro Peri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. INTRODUCTION

Neuroblastoma (NB), the most common extracranial solid tumor in children, accounts for more than 7% of malignancies in patients younger than 15 years and around 15% of all pediatric oncology deaths [1]. The disease has a heterogeneous clinical presentation and course [2]. First of all, NB is a disease of the sympathetic-adrenal lineage of the neural crest, and therefore tumors can develop anywhere in the sympathetic nervous system. The majority of NB is developed within the abdomen and at least 50% of these tumors arise in the adrenal medulla [2]. Other frequent localizations include the neck, chest, and pelvis [3]. The clinical presentation of the disease may be also highly variable and depends on the site of the primary tumor as well as on the presence or absence of metastatic disease (mostly hematogeneous dissemination to cortical bone, bone marrow, liver, and noncontiguous lymph nodes) or paraneoplastic syndromes. The diagnosis of NB is based on histopathological assessment of tumor tissue or on the detection of cancer cells in a bone marrow aspirate/biopsy, together with the presence of increased levels of urinary catecholamines [2]. Imaging studies for the localization of the disease include computed tomography, magnetic resonance, \(^{99}\)Tc-diphosphonate, or metaiodobenzylguanidine (using \(^{123}\)I) scintigraphy for the detection of bone metastases.
attractive therapeutic option and clinical trials are ongoing. Retinoids have been shown to interfere with cell growth and to induce apoptosis in NB cells [39, 40] and preliminary clinical trials with retinoids in NB resulted in improved event-free survival in high-risk patients, with limited toxic effects [41, 42]. Thiazolidinediones (TZDs) are a class of molecules that activate the nuclear receptor peroxisome proliferator-activated receptor γ (PPARγ) [43] and promote association with the 9-cis retinoic X receptor (RXR) to form functional heterodimers that recognize its cognate DNA response element within target genes [44, 45]. TZDs have been shown to have antineoplastic effects, as extensively discussed in this issue of the journal, in agreement with the demonstration that PPARγ/RXR signalling exerts an important role in inhibiting cell proliferation and/or in inducing apoptosis [46]. It has been also shown that PPARγ and RXR ligands may have a synergistic effect in inducing cell differentiation [47, 48] and in inhibiting cell growth in different tumors, such as colon, lung, and breast cancer [49–51]. There is evidence that also PPARα and PPARβ ligands may play a role in counteracting tumoral cell growth and in promoting cell differentiation, including neuroblastoma cells [52, 53]. However, most of the reports covering this issue, that have been published in the literature so far, deal with PPARγ agonists. Therefore, the role of PPARγ ligands as a possible therapeutic option in NB is reviewed and discussed here.

2. PPARγ AND PPARγ AGONISTS IN NEUROBLASTOMA

The first demonstration that PPARγ is expressed in NB cells was provided by Han et al. in 2001 [54]. Using RT-PCR the authors showed that LA-N-5 NB cells express also PPARβ, but not PPARα. Similarly, in sections from human primary NB immunostaining for PPARγ was detected in the nucleus and occasionally in the cytoplasm of cells, particularly in those showing ganglionic differentiation. Sato et al. [55] addressed the possibility that the amount of expression of PPARγ in NB might be correlated to patients’ outcome. To this purpose, the level of mRNA was measured by semiquantitative RT-PCR in NB samples from 17 patients under the age of one year. In this subset of patients, spontaneous differentiation and regression are often observed [56], and some investigators suggested to observe these patients without surgery until there is an increase of vanilmandelic acid (VMA) or tumoral growth occurs [57, 58]. PPARγ mRNA was present in 12 samples. No difference between the expression of PPARγ and histology, age, staging, DNA ploidy was observed, yet a correlation with the change in urinary VMA was found. In fact, in samples resected from patients, who showed a reduction of VMA in the period of time preceding surgery (2–7 months), higher PPARγ expression was detected compared to those patients in which VMA increased. The authors hypothesized that PPARγ might play a role in the decrease of VMA and hence in the regression of early-onset NB. Thereafter, several studies addressed the potential role of endogenous or synthetic PPARγ ligands in counteracting NB cell growth.

5-Deoxy-Δ12,14-prostaglandin J₂ (15-deoxy-PGJ₂) is a naturally occurring downstream metabolite of PGD₂, that is produced by degradation of PGD₂ [59]. In contrast to classic prostaglandins, which act after binding to cell surface G-protein coupled receptors (GPCRs), 15-deoxy-PGJ₂ is a high-affinity endogenous ligand of PPARγ. A pro-apoptotic effect of 15-deoxy-PGJ₂ in SH-SY5Y NB cells, that was reverted by the caspase inhibitor Z-VAD, was reported by Rohn et al. [60]. A subsequent study confirmed that 15-deoxy-PGJ₂ was able to inhibit cell growth and to induce apoptosis via the activation of ERK2 in two additional NB cell lines (i.e., SK-N-SH and SK-N-MC). An increase of the expression of the pro-apoptotic proteins caspase-3, caspase-9, and Bax, together with the decrease of the anti-apoptotic protein Bcl-2, was also observed [61]. The PPARγ antagonist GW9662 reverted the effects of 15-deoxy-PGJ₂, including the activation of ERK2. The authors concluded that 15-deoxy-PGJ₂ induced apoptosis in a PPARγ-dependent manner through the activation of ERK pathway. Another study showed that the mechanism by which 15-deoxy-PGJ₂ arrests cell growth may vary depending on the content of lipids in the culture medium [62]. In particular, the delipidation of fetal calf serum, which removes known serum lipid mitogens including lysophosphatidic acid [63] and sphingosine 1-phosphate [64], potentiated the degree of 15-deoxy-PGJ₂-induced growth inhibition via PPARγ-dependent apoptosis in the NB cell line IMR-32. Conversely, growth inhibition in the presence of complete medium occurred through programmed cell death type1 (autophagy).

PPARγ-independent effects of 15-deoxy-PGJ₂ have been also described. Jung et al. reported that this PPARγ ligand was able to increase NGF-induced differentiation of PC-12 NB cells, as assessed by neurite extension and expression of neurofilament [65]. Pretreatment with the PPARγ antagonist bisphenol A diglycidyl either did not alter the differentiating activity of 15-deoxy-PGJ₂. The fact that PC-12 cells do not express PPARγ further supported the hypothesis that the biological effects elicited by 15-deoxy-PGJ₂ were not mediated by this receptor. Conversely, 15-deoxy-PGJ₂ enhanced NGF-induced p38 MAP kinase expression and phosphorylation as well as the activation of transcription factor AP-1, that on turn were counteracted by a specific inhibitor of p38 MAP kinase (SB203580). Altogether, these data suggested that the promoting effect of 15-deoxy-PGJ₂ on cell differentiation may be mediated by the activation of p38 MAP kinase in conjunction with the AP-1 signalling pathway.

Other studies addressed the role of synthetic PPARγ ligands in counteracting cell growth in NB. In the already mentioned work by Han et al., in which the presence of PPARγ in NB cells was described for the first time, the authors also demonstrated that the synthetic PPARγ agonist GW1929 induced the differentiation of LA-N-5 cells and inhibited cell proliferation [54]. A subsequent study of the same group showed that the prodifferentiating effect of GW1929 is mediated by PPARγ, because it was inhibited by the cotreatment with specific antagonists [66]. The antiproliferative effects of the TZDs ciglitazone, pioglitazone, troglitazone, and rosiglitazone in different NB cell lines (i.e., LAN-1, LAN-5, LS, IMR-32, SK-N-SH, SH-SY5Y) were
determined by Valentiner et al. [67]. In these cell lines, which express PPARγ, the four ligands were able to markedly inhibit cell growth at the highest doses that were used (10 and 100 μM). Ciglitazone determined the strongest inhibitory effect (more than 90% inhibition). The potency of the different PPARγ ligands was not related to the amount of expression of PPARγ in NB cell lines. Thus, the authors hypothesized that the effects of the molecules that were used seem to be independent of the amount of PPARγ protein in one particular cell line. Conversely, they concluded that the response to PPARγ ligands may rather depend on various cellular conditions, which are associated with the function of the receptor, such as its activation, translocation to the nucleus and binding to PPAR response elements (PPRE). The role played by PPARγ transactivation was confirmed by the finding that growth inhibition determined by 15-deoxy-PGJ2 and ciglitazone in NB cells was counteracted by the repression of PPARγ transactivation via retinoblastoma protein overexpression [68]. Further studies investigated whether the inhibitory effect of TZDs on cell growth was mediated, at least partially, by a stimulatory effect on apoptosis. Kato et al. found that in NB-1 cells troglitazone induced PPARγ-dependent apoptosis [69]. Similar data were reported later on by Schultz et al. [70], who showed that in SHEP NB cells the pro-apoptotic effect of the death ligand TRAIL is reinforced by troglitazone. However, troglitazone-induced sensitization to TRAIL appeared to be PPARγ-independent, because it was achieved at concentrations that failed to activate PPARγ. Conversely, the authors highlighted the fact that troglitazone may induce apoptotic death by various PPARγ-independent mechanisms. In particular, troglitazone led to a marked downregulation of the antiapoptotic protein Survivin, as well as to an upregulation of the agonistic TRAIL receptor TRAIL-R2.

Overall, these data strongly indicate that PPARγ ligands are able to effectively counteract cell growth and to induce apoptosis in NB cells. Undoubtedly, the role of PPARγ in eliciting these responses would be further clarified by studies designed for instance to manipulate gene expression (i.e., by small interfering RNA or dominant negative strategies). To our knowledge, there are only two reports from one Korean group showing, in contrast to the current opinion, that a PPARγ agonist (i.e., rosiglitazone) protects NB (SH-SY5Y) cells against the neurotoxins acetaldehyde and 1-methyl-4-phenylpyridinium ion, through inhibition of apoptosis [71, 72].

3. DIFFERENTIAL PPARγ TRANSACTIVATION IN NEOBlastoma CELL LINES WITH A DIFFERENT PHENOTYPE: RELATIONSHIP WITH THE RESPONSE TO ROSIGLITAZONE

NB is a phenotypically heterogeneous tumor, displaying cells of neuronal, melanocytic, or glial/schwannian lineage. This cellular heterogeneity is also present in vitro, where cells of neuroblastic (N) or stromal (S) type may be identified. It has been hypothesized that the sensitivity to PPARγ ligands may be, at least partially, dependent on the different cell phenotype. To this purpose, Servidei et al. examined the response of 8 different NB cell lines with N (SH-SY5Y, LA-N-5, SMS-KCN, SK-N-DZ), mixed (SK-N-FI, LA-N-1), or S (SH-EP1, SK-N-AS) phenotype to PPARγ agonists [73]. All the cell lines investigated expressed a functionally active PPARγ. 15-deoxy-PGJ2 and rosiglitazone inhibited cell growth in all cell lines, and the sensitivity appeared to be more related to the cell phenotype than to PPARγ expression. In particular, the N type cells appeared the most sensitive to treatment. In this experimental setting, the cotreatment with PPARγ ligands and the RXR ligand 9-cis retinoic acid did not determine any synergistic effect on growth inhibition. The more evident response of N type cells to PPARγ ligands was in part related to their higher capability to undergo apoptosis, although only 15-deoxy-PGJ2 appeared to effectively induce the apoptotic cascade in these cells. It has to be said that in this study some experimental observations (i.e., apoptosis and cell viability) were not performed in all the investigated NB cell lines.

In order to further clarify the mechanisms underlying the response of NB cells to PPARγ agonists, we compared the response of two cell lines (SH-SY5Y, N type, and SK-N-AS, S type) to rosiglitazone. In contrast to the above-mentioned findings, we observed that micromolar concentrations of rosiglitazone inhibited cell proliferation and reduced cell viability more effectively in SK-N-AS than in SH-SY5Y [74]. The PPARγ antagonist BADGE reverted the effect of rosiglitazone, thus suggesting a direct role of PPARγ in mediating the effects of this agonist on cell proliferation and viability. In addition, we found that SK-N-AS cells were more sensitive to rosiglitazone in terms of reduction of cell adhesion and invasiveness. The latter effect was in agreement with rosiglitazone-dependent reduced expression of matrix metalloproteinase-9 (MMP-9). In addition, rosiglitazone determined a trend toward increased expression levels of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1). MMPs, which promote the invasion of extracellular matrix by tumoral cells, have been related to the progression of different tumors, including NB [75, 76]. In our study, we also addressed the possible role of rosiglitazone in inducing apoptosis. We demonstrated that micromolar concentrations of this molecule were able to induce caspase-3 activation in SK-N-AS, but not in SH-SY5Y (up to 50 μM). Therefore, all our data indicated that rosiglitazone played an effective antitumoral role in the S type SK-N-AS, yet not in the N type SH-SY5Y NB cells. Although our study was limited to two cell lines, this apparent prevalent effect on a particular cell phenotype may have clinical resonance. In fact, it is known that in NB, following cytotoxic therapy, the residual tumor often shows a reduction of the neuroblastic elements and the persistence of stromal components [77]. Hence, a molecule that appears to have S type NB cells as a preferential target might be of interest in the setting of residual disease.

A further aim of our study was to determine the reason underlying the peculiar sensitivity to rosiglitazone displayed by SK-N-AS cells. Both SK-N-AS and SH-SY5Y expressed a similar amount of PPARγ. However, in transient transfection experiments, in which a PPRE-thimidine kinase luciferase reporter plasmid was inserted, we observed that in SK-N-AS 20 μM rosiglitazone induced a near three-fold increase of the
reporter activity compared to untreated cells. Conversely, no effect was elicited in SH-SY5Y. Only when these cells were co-transfected with PPARγ expression plasmid, the response to rosiglitazone was present. These data indicated that the original lack of response showed by SH-SY5Y was due to a very low or absent transactivation potential of the endogenous PPARγ (Figure 1). The different efficacy of PPARγ as a transcriptional activator in the two cell lines might be hypothetically due to the presence of a PPARγ gene mutation. However, no mutation was found in the entire coding region of the gene. Conversely, we found that the amount of phosphorylated PPARγ was markedly lower in SK-N-AS than in SH-SY5Y cells (Figure 2). There is evidence that phosphorylation reduces the activity of the receptor [78]. Therefore, our conclusion was that the higher efficacy of rosiglitazone in SK-N-AS cells was due to a reduced phosphorylation status, hence to increased activity, of PPARγ. To our knowledge, this was the first demonstration that the response of NB cells to TZDs may be dependent on PPARγ transactivation.

4. PPARγ AGONISTS IN NEUROBLASTOMA XENOGRAFT MODELS

To our knowledge, no study on the in vivo effect of TZDs in neuroblastoma has been published so far. However, our very recent preliminary in vivo observations on CD-1 athymic nude mice, in which SK-N-AS cells were subcutaneously inoculated, appear to confirm our previous in vitro observations [74]. Rosiglitazone (150 mg/kg/day, in agreement with the average dose used in other in vivo studies addressing different tumors) was administered by gavage for 4 weeks.

Figure 2: Detection of total (anti-PPARγ antibody) and phosphorylated (anti-P-Ser antibody) PPARγ, by Western blot analysis after PPARγ immunoprecipitation (from [74], modified).

Tumoral growth was markedly reduced compared to control mice, treated with the vehicle alone. At the end of treatment, the weight of the tumor in rosiglitazone-treated animals was about 60% less than in control animals [Cellai et al; unpublished data]. An extensive molecular characterization of tumor specimens is currently ongoing, in order to elucidate the mechanisms underlying the growth inhibitory effect of rosiglitazone observed in vivo in our xenograft model.

5. CONCLUSIONS

In the last few years in vitro studies have shown that PPARγ agonists may inhibit NB cell growth by stimulating cell differentiation and/or by inducing apoptosis. The different molecules that have been tested have generally produced similar results. However, the mode of action may change depending on the agonist and/or on the different cell line used. In addition, both PPARγ-dependent as well as PPARγ-independent effects have been described. Our recent data suggest that PPARγ transactivation, determined at least in part by the phosphorylation status of the receptor, may play an important role in determining the response of NB cells to PPARγ agonists. However, the exact mechanisms of action and the possibility to predict the success or failure of the treatment of NB with these molecules are, at this time, matter of further in vitro as well as in vivo research.

ACKNOWLEDGMENTS

The authors wish to thank the people who collaborated to in vitro and in vivo studies [67, Cellai et al., unpublished data], and in particular Professor Andrea Galli (Gastroenterology Unit, Department of Clinical Physiopathology, University of Florence), Doctor Lisa Simi (Clinical Biochemistry Unit, Department of Clinical Physiopathology, University of Florence), Doctor Monica Muratori (Andrology Unit, Department of Clinical Physiopathology, University of Florence), Doctor Graziella Pratesi (Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan), and Doctor Carol J Thiele (Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.) These studies were partially supported by granto from Enta Cassadi Risparimo, Firenze and from Regione Toscana Ctesor Project, Principal Investigator Professor Mario Seriol.
REFERENCES

[1] National Cancer Institute, Surveillance, Epidemiology and End Results Database, November 2005, http://seer.cancer.gov.

[2] J. M. Maris, M. D. Hogarty, R. Bagatell, and S. L. Cohn, “Neuroblastoma,” The Lancet, vol. 369, no. 9579, pp. 2106–2120, 2007.

[3] G. M. Brodeur and J. M. Maris, “Neuroblastoma,” in Principles and Practice of Pediatric Oncology, P. A. Pizzo and D. G. Poplack, Eds., pp. 933–970, JB Lippincott Company, Philadelphia, Pa, USA, 5th edition, 2006.

[4] N. K. Cheung, B. H. Kushner, M. LaQuaglia, et al., “N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age,” Medical and Pediatric Oncology, vol. 36, no. 1, pp. 227–230, 2001.

[5] B. De Bernardi, B. Nicolas, L. Boni, et al., “Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma,” Journal of Clinical Oncology, vol. 21, no. 8, pp. 1592–1601, 2003.

[6] K. K. Matthay, J. G. Villablanca, R. C. Seeger, et al., “Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid,” The New England Journal of Medicine, vol. 341, no. 16, pp. 1165–1173, 1999.

[7] L. M. Wagner, K. R. Crews, L. C. Iacono, et al., “Phase II trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors,” Clinical Cancer Research, vol. 10, no. 3, pp. 840–848, 2004.

[8] G. Vassal, F. Doz, D. Frappaz, et al., “A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors,” Journal of Clinical Oncology, vol. 21, no. 20, pp. 3844–3852, 2003.

[9] R. L. Saylors III, K. C. Stine, J. Sullivan, et al., “Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study,” Journal of Clinical Oncology, vol. 19, no. 15, pp. 3463–3469, 2001.

[10] A. Längler, A. Christaras, K. Abshagen, K. Krauth, B. Hero, and F. Berthold, “Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood—a phase-II-study,” Klinische Pädiatric, vol. 214, no. 4, pp. 153–156, 2002.

[11] S. Tepmongkol and S. Heyman, “131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status,” Medical and Pediatric Oncology, vol. 32, no. 6, pp. 427–432, 1999.

[12] K. K. Matthay, K. DeSantes, B. Hasegawa, et al., “Phase I dose escalation of 131-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma,” Journal of Clinical Oncology, vol. 16, no. 1, pp. 229–236, 1998.

[13] A. Garaventa, O. Bellagamba, M. S. Lo Piccolo, et al., “131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients,” British Journal of Cancer, vol. 81, no. 8, pp. 1378–1384, 1999.

[14] G. A. Wiseman and L. K. Kools, “Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues,” Seminars in Nuclear Medicine, vol. 25, no. 3, pp. 272–278, 1995.

[15] M. S. O’Dorisio, M. Hauger, and A. J. Cecalupo, “Somatostatin receptors in neuroblastoma: diagnostic and therapeutic implications,” Seminars in Oncology, vol. 21, supplement 13, no. 5, pp. 33–37, 1994.

[16] P. Borgström, M. Hassan, E. Wåsberg, et al., “The somatostatin analogue octreotide inhibits neuroblastoma growth in vivo,” Pediatric Research, vol. 46, no. 3, pp. 328–332, 1999.

[17] A. L. Yu, M. M. Utenreuther-Fischer, C. S. Huang, et al., “Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma,” Journal of Clinical Oncology, vol. 16, no. 6, pp. 2169–2180, 1998.

[18] N. K. Cheung, B. H. Kushner, S. D. J. Yeh, and S. M. Larson, “3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study,” International Journal of Oncology, vol. 12, no. 6, pp. 1299–1306, 1998.

[19] B. H. Kushner, K. Kramer, and N.-K. V. Cheung, “Phase II trial of the anti-GD2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma,” Journal of Clinical Oncology, vol. 19, no. 22, pp. 4189–4194, 2001.

[20] T. I. Kang, P. Brophy, M. Hixson, et al., “Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma,” Journal of Pediatric Hematology/Oncology, vol. 25, no. 10, pp. 769–773, 2003.

[21] J. P. Howard, J. M. Maris, L. S. Kersun, et al., “Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma,” Pediatric Blood and Cancer, vol. 44, no. 3, pp. 232–239, 2005.

[22] S. G. DuBois, J. Messina, J. M. Maris, et al., “Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma,” Journal of Clinical Oncology, vol. 22, no. 12, pp. 2452–2460, 2004.

[23] Z. C. Neal, J. C. Yang, A. L. Rakhmilevich, et al., “Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy,” Clinical Cancer Research, vol. 10, no. 14, pp. 4839–4847, 2004.

[24] D. M. King, M. R. Albertini, H. Schalch, et al., “Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients,” Journal of Clinical Oncology, vol. 22, no. 22, pp. 4463–4473, 2004.

[25] A. Yu, A. Batova, D. Strother, P. Angelini, and R. P. Castleberry, “Promising results of a pilot trial of a GD2 directed anti-idiotypic antibody as vaccine for high risk neuroblastoma,” in Proceedings of the 11th Conference on Advances in Neuroblastoma Research (ANR ’04), vol. 75, Genoa, Italy, June 2004.

[26] S. Gonzalez, A. Naranjo, L. M. Serrano, W.-C. Chang, C. L. Wright, and M. C. Jensen, “Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma,” The Journal of Gene Medicine, vol. 6, no. 6, pp. 704–711, 2004.

[27] H. M. Katzenstein, A. W. Rademaker, C. Senger, et al., “Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden,” Clinical Cancer Research, vol. 5, no. 12, pp. 4273–4278, 1999.

[28] S. Shusterman, A. Naranjo, L. M. Serrano, W.-C. Chang, C. L. Wright, and M. C. Jensen, “Gene therapy of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma,” Seminars in Nuclear Medicine, vol. 25, no. 3, pp. 272–278, 1995.

[29] M. S. O’Dorisio, M. Hauger, and A. J. Cecalupo, “Somatostatin receptors in neuroblastoma: diagnostic and therapeutic implications,” Seminars in Oncology, vol. 21, supplement 13, no. 5, pp. 33–37, 1994.
[59] M. Fukushima, “Biological activities and mechanisms of action of PGJ$_2$ and related compounds: an update,” Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 47, no. 1, pp. 1–12, 1992.

[60] T. T. Rohn, S. M. Wong, C. W. Cotman, and D. H. Cribbs, “15-deoxy-Δ$^{12,14}$-prostaglandin J$_2$, a specific ligand for peroxisome proliferator-activated receptor-γ, induces neuronal apoptosis,” NeuroReport, vol. 12, no. 4, pp. 839–843, 2001.

[61] E. J. Kim, K. S. Park, S. Y. Chung, et al., “Peroxisome proliferator-activated receptor-γ activator 15-deoxy-Δ$^{12,14}$-prostaglandin J$_2$ inhibits neuroblastoma cell growth through induction of apoptosis: association with extracellular signal-regulated kinase signal pathway,” Journal of Pharmacology and Experimental Therapeutics, vol. 307, no. 2, pp. 505–517, 2003.

[62] H. A. Rodway, A. N. Hunt, J. A. Kohler, A. D. Postle, and K. A. Lillycrop, “Lysophosphatidic acid attenuates the cytotoxic effects and degree of peroxisome proliferator-activated receptor-γ activation induced by 15-deoxyΔ$^{12,14}$-prostaglandin J$_2$ in neuroblastoma cells,” Biochemical Journal, vol. 382, part 1, pp. 83–91, 2004.

[63] T. Eichholtz, K. Jalink, I. Fahrenfort, and W. H. Moolenaar, “The bioactive phospholipid lysophosphatidic acid is released from activated platelets,” Biochemical Journal, vol. 291, part 3, pp. 677–680, 1993.

[64] Y. Yatomi, Y. Igarashi, L. Yang, et al., “Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum,” Journal of Biochemistry, vol. 121, no. 5, pp. 969–973, 1997.

[65] K. M. Jung, K. S. Park, J. H. Oh, et al., “Activation of p38 mitogen-activated protein kinase and activator protein-1 during the promotion of neurite extension of PC-12 cells by 15-deoxy-Δ$^{12,14}$-prostaglandin J$_2$,” Molecular Pharmacology, vol. 63, no. 3, pp. 607–616, 2003.

[66] S. Han, R. K. Wada, and N. Sidell, “Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferator-activated receptor-γ,” Cancer Research, vol. 61, no. 10, pp. 3998–4002, 2001.

[67] U. Valentiner, M. Carlsson, R. Erttmann, H. Hildebrandt, and U. Schumacher, “Ligands for the peroxisome proliferator-activated receptor-γ have inhibitory effects on growth of human neuroblastoma cells in vitro,” Toxicology, vol. 213, no. 1–2, pp. 157–168, 2005.

[68] V. C. Emmans, H. A. Rodway, A. N. Hunt, and K. A. Lillycrop, “Regulation of cellular processes by PPARγ ligands in neuroblastoma cells is modulated by the level of retinoblastoma protein expression,” Biochemical Society Transactions, vol. 32, part 5, pp. 840–842, 2004.

[69] M. Kato, T. Nagaya, M. Fujieda, K. Saito, J. Yoshida, and H. Seo, “Expression of PPARγ and its ligand-dependent growth inhibition in human brain tumor cell lines,” Japanese Journal of Cancer Research, vol. 93, no. 6, pp. 660–666, 2002.

[70] K. Schultze, B. Böck, A. Eckert, et al., “Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin,” Apoptosis, vol. 11, no. 9, pp. 1503–1512, 2006.

[71] T. W. Jung, J. Y. Lee, W. S. Shim, et al., “Rosiglitazone protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity,” Biochemical and Biophysical Research Communications, vol. 340, no. 1, pp. 221–227, 2006.

[72] T. W. Jung, J. Y. Lee, W. S. Shim, et al., “Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production,” Journal of the Neurological Sciences, vol. 253, no. 1–2, pp. 53–60, 2007.

[73] T. Servidei, R. Morosetti, C. Ferlini, et al., “The cellular response to PPARγ ligands is related to the phenotype of neuroblastoma cell lines,” Oncology Research, vol. 14, no. 7-8, pp. 345–354, 2004.

[74] I. Cellai, S. Benvenuti, P. Luciani, et al., “Antineoplastic effects of rosiglitazone and PPARγ transactivation in neuroblastoma cells,” British Journal of Cancer, vol. 95, no. 7, pp. 879–888, 2006.

[75] Y. Sugiura, H. Shimada, R. C. Seeger, W. E. Laug, and Y. A. DeClerck, “Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis,” Cancer Research, vol. 58, no. 10, pp. 2209–2216, 1998.

[76] C. F. Chantrain, H. Shimada, S. Jodele, et al., “Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment,” Cancer Research, vol. 64, no. 5, pp. 1675–1686, 2004.

[77] S. Ogita, K. Tokiwa, N. Arizono, and T. Takahashi, “Neuroblastoma: incomplete differentiation on the way to maturation or morphological alteration resembling maturity?” Oncology, vol. 45, no. 3, pp. 148–152, 1988.

[78] D. Shao and M. A. Lazar, “Modulating nuclear receptor function: may the phos be with you,” Journal of Clinical Investigation, vol. 103, no. 12, pp. 1617–1618, 1999.